Safety board supports further PBGENE-DMD dosing after first patient's eight-week review
Company / institutional announcement · Precision BioSciences / Business Wire
Source published: · Event / reporting date: 2026-11-05
Site published: 2026-11-06 · Updated: 2026-11-06
This source is linked automatically. Choose a question to get started.
What changed
Precision BioSciences said an independent safety board endorsed additional dosing in the Phase 1/2 FUNCTION-DMD study after reviewing the first PBGENE-DMD recipient's eight-week observation period. No serious adverse events or adverse events of special interest were reported in that patient. The AAV-delivered gene-editing program remains investigational; this single-patient review does not establish efficacy or broader safety.
Why it may matter
Analysis: This milestone may enable broader early clinical evaluation of muscle-directed editing while emphasizing the need for continued AAV-related safety surveillance.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections